Trials Sponsors Conditions Drugs Pricing

Conditions

Obese Adolescents Obesity

Keywords

Weight managementobesityXW003ecnoglutideglucagon-like peptide-1 (GLP-1)adolescent

Outcome Measures

Primary Outcomes (1)

Number and severity of adverse events
week 20

Secondary Outcomes (2)

Plasma concentrations of XW003
week 20
Change of body weight from baseline
week 20

Study Arms (4)

XW003 Dose 1

EXPERIMENTAL

once weekly

Drug: XW003 injection

XW003 Dose 2

EXPERIMENTAL

once weekly

Drug: XW003 injection

XW003 Dose 3

EXPERIMENTAL

once weekly

Drug: XW003 injection

Interventions

XW003 injectionDrug

Subcutaneous injection

XW003 Dose 1XW003 Dose 2XW003 Dose 3

placebo with matching volumeDrug

Subcutaneous injection

placebo

Eligibility Criteria

Age12 Years - 18 Years

Sexall(Gender-based eligibility)

Healthy VolunteersYes

Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

At the time of screening, BMI meets the obesity criteria specified in WS/T586-2018 'screening for overweight and obesity among school-aged children and adolescents', and weight ≥55 kg;
At the time of screening, the decrease of body mass index less than 5% after diet and exercise control alone for at least 12 weeks (as reported by participants or parents or legal guardians);

Sponsors & Collaborators

Hangzhou Sciwind Biosciences Co., Ltd.
Industrylead

Study Sites (1)

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

Wei Zhao, Dr
Qilu Hospital of Shandong University
PRINCIPAL INVESTIGATOR
Xinguo Hou, Dr
Qilu Hospital of Shandong University
PRINCIPAL INVESTIGATOR

Enrollment

48 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: RANDOMIZED
Masking: DOUBLE
Who Masked: PARTICIPANT, INVESTIGATOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 13, 2025

First Posted

August 27, 2025

Study Start

August 25, 2025

Actual (reported)

A Study of XW003 Injection in Chinese Adolescents With Obesity

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

XW003 Dose 1

XW003 Dose 2

XW003 Dose 3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

placebo

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

Study Start

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (4)

XW003 Dose 1

XW003 Dose 2

XW003 Dose 3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

placebo

You may not qualify if:

Data Sharing

Source record

Locations